Personal injury lawyers say Bayer AG and Janssen failed to warn patients and the medical community about the risks of irreversible bleeding; and
Bayer AG and Janssen negligently placed a dangerous product in the market that did not offer any benefits over other existing products that outweighed the risks.
This lawsuit was filed on July 25, 2014 in federal court under case number 2:14-CV-00159 by the daughter of a deceased man who succumbed to internal bleeding that the lawsuit alleged was caused by Xarelto.
A Summary Of The Xarelto Lawsuit
The decedent was prescribed Xarelto by his doctor to prevent blood clots and stroke for atrial fibrillation, a heart condition for which Xarelto is FDA approved to treat. After taking Xarelto, the decedent was admitted to hospital for a brain bleed, which was diagnosed as a parenchymal hemorrhage. The blood thinner prevented the decedent’s blood from clotting and stopping the bleed, which unfortunately lead to the death of the plaintiff’s father. According to the complaint, the plaintiff’s father was hospitalized for 6 days while extreme measures were taken to stem the bleeding. While the complaint did not identify what caused the brain bleed to commence, a parenchymal hemorrhage usually occurs in patients with hypertension or from some form of head trauma.
What Is The Problem With Xarelto?
Xarelto is a new form of blood thinner that is marketed by it’s manufacturers for its convenience compared to traditional blood thinners like Warfarin. The marketing for Xarelto states that there is one uniform dose which does not require frequent blood monitoring. The main problem with Xarelto is that there is no known antidote that can reverse the anti-coagulation effect of the drug. For Warfarin, a dosage of vitamin K will assist coagulation. Xarelto is part of a class of Xa inhibitor, which is not effected by Vitamin K. As a result, this lawsuit, along with many other Xarelto wrongful death and personal injury lawsuits are based on claims that the manufacturers were negligent to place this blood thinner in the market where there was no reversal agent.